Flavivirus Entry Inhibitors

详细信息    查看全文

• 作者：Qing-Yin Wang ; Pei-Yong Shi
• 刊名：ACS Infectious Diseases
• 出版年：2015
• 出版时间：September 11, 2015
• 年：2015
• 卷：1
• 期：9
• 页码：428-434
• 全文大小：337K
• ISSN：2373-8227

文摘

Many flaviviruses are significant human pathogens that are transmitted by mosquitoes and ticks. Although effective vaccines are available for yellow fever virus, Japanese encephalitic virus, and tick-borne encephalitis virus, these and other flaviviruses still cause thousands of human deaths and millions of illnesses each year. No clinically approved antiviral therapy is available for flavivirus treatment. To meet this unmet medical need, industry and academia have taken multiple approaches to develop antiflavivirus therapy, among which targeting viral entry has been actively pursued in the past decade. Here we review the current knowledge of flavivirus entry and its use for small molecule drug discovery. Inhibitors of two major steps of flaviviral entry have been reported: (i) molecules that block virus–receptor interaction; (ii) compounds that prevent conformational change of viral envelope protein during virus–host membrane fusion. We also discuss the advantages and disadvantages of targeting viral entry for treatment of flavivirus infection as compared to targeting viral replication proteins.